Please ensure Javascript is enabled for purposes of website accessibility

Gilead Has Treated More Than 1,700 COVID-19 Patients With Remdesivir

By Brian Orelli, PhD - Apr 5, 2020 at 11:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech has manufactured enough doses to treat over 140,000 patients infected with the new coronavirus and is looking to further ramp up production.

Gilead Sciences (GILD 0.08%) has made remdesivir, its Ebola-turned-COVID-19 drug, available to more than 1,700 patients through compassionate-use and expanded-access programs, according to an update from Gilead's chairman and CEO, Daniel O'Day, that was posted on the company's website on Saturday.

The number of COVID-19 patients treated with remdesivir is likely to go higher. On Friday, EU regulators recommended expanding access to remdesivir for patients who are unable to partake in one of the nine clinical trials testing remdesivir that are ongoing or in the process of being set up.

Because remdesivir isn't approved to treat any disease -- it was never approved to treat Ebola given the lackluster clinical trial results and the waning Ebola virus outbreak -- there wasn't a warehouse full of the drug nor a manufacturing plant set up for large-scale production.

Patient and her doctors in a restricted area

Image source: Getty Images.

Fortunately, Gilead recognized the potential for remdesivir to treat COVID-19 early and increased production at risk. O'Day noted: "Then, as now, there were many unknowns including how long the outbreak would last, at what scale, and whether remdesivir is a safe and effective treatment for COVID-19. We made the decision to invest and scale up regardless, because if remdesivir was going to be needed for patients, we had to be ready."

Through improved production times and increasing manufacturing at external partners, Gilead has been able to manufacture 1.5 million doses, which should be able to treat over 140,000 patients depending on the optimal dose, which is still being determined.

Longer term, Gilead is looking to have enough drug to treat more than 500,000 patients by October and more than 1 million treatment courses by the end of this year.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.65 (0.08%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.